[Skip to Navigation]
Comment & Response
September 23, 2020

Redefining Left Ventricular Assist Device Indications and Strategies

Author Affiliations
  • 1Division of Cardiology, Department of Medicine, The University of Tennessee Medical Center, Knoxville
JAMA Cardiol. 2021;6(1):119-120. doi:10.1001/jamacardio.2020.4320

To the Editor In a prespecified analysis of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM III) trial, Goldstein et al1 demonstrated that the superior treatment effect of the HeartMate 3 over HeartMate II was similar regardless of current or future transplant eligibility and that clinical dispositions were dynamic. The authors proposed abandoning discrete transplant eligibility labels in favor of a single preimplant strategy.1 Could there be value in translating the success achieved by the use of the more hemocompatible HeartMate 3 system to refine rather than unify the implant strategy? The paradigm of value-based care and myocardial recovery may favor the former approach.

Add or change institution